-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Inozyme Pharma, Lowers Price Target to $23

Benzinga·03/11/2025 16:05:45
Listen to the news
Piper Sandler analyst Allison Bratzel maintains Inozyme Pharma (NASDAQ:INZY) with a Overweight and lowers the price target from $30 to $23.